A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist

David Kudrow, Linda Nguyen, Jack Semler, Chad Stroud, Karen Samaan, Deirdre B. Hoban, Linda Wietecha, Hai‐An Hsu, Eric Pearlman

Open source

DOI
10.1111/head.14390
Published
2022-09-16
Container
Headache: The Journal of Head and Face Pain
Publisher
Wiley
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1111/head.14390,
  title = {A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist},
  author = {David Kudrow and Linda Nguyen and Jack Semler and Chad Stroud and Karen Samaan and Deirdre B. Hoban and Linda Wietecha and Hai‐An Hsu and Eric Pearlman},
  year = {2022},
  journal = {Headache: The Journal of Head and Face Pain},
  doi = {10.1111/head.14390},
  url = {https://doi.org/10.1111/head.14390}
}

RIS

TY  - JOUR
TI  - A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
AU  - David Kudrow
AU  - Linda Nguyen
AU  - Jack Semler
AU  - Chad Stroud
AU  - Karen Samaan
AU  - Deirdre B. Hoban
AU  - Linda Wietecha
AU  - Hai‐An Hsu
AU  - Eric Pearlman
PY  - 2022
JO  - Headache: The Journal of Head and Face Pain
DO  - 10.1111/head.14390
UR  - https://doi.org/10.1111/head.14390
ER  - 

APA

Kudrow, D., Nguyen, L., Semler, J., Stroud, C., Samaan, K., Hoban, D. B., Wietecha, L., Hsu, H., & Pearlman, E. (2022). A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14390

Source records